The Memo: Updates From the Alumni

In this special edition of The Memo, we’re revisiting five standout companies previously featured in our series, each of which has recently reached a significant funding or strategic milestone. From advanced biomaterials to next-generation robotics, these medtech innovators are continuing to push their technologies forward, securing the resources and partnerships needed to scale. The companies featured below were originally selected for their bold ideas, mission-driven teams, and transformative potential. Today, they are proving that momentum is not just possible; it’s underway.

Aortyx

Company Insights: Barcelona-based Aortyx is developing a novel, bioresorbable patch designed to treat aortic dissection through a minimally invasive approach. The patch is delivered via a dual steerable catheter and is engineered to integrate with the body’s own tissue, mimicking the natural mechanical properties of the aorta. With a platform rooted in vascular biology, biomechanics, and fluid dynamics, the company aims to address the urgent need for safer and more effective alternatives to open surgery and limited endovascular solutions.

Market Opportunity: Aortic dissection is a rare condition associated with very high mortality, particularly when the onset is acute. Solutions for treating aortic disease include endovascular stent grafts, which make up a $1.6 billion global market.

Update: In June 2025, Aortyx announced the close of a $16 million (€13.8 million) funding round. Investors included Ship2B Ventures, Clave Capital, the EIC Fund, CDTI Innvierte, and an undisclosed leading aortic device manufacturer. The funding will support the company’s progression toward first-in-human trials within two years.

Berlin Heals

Company Insights: Berlin Heals is on a mission to reverse the course of heart failure with its small implantable device, C-MIC. The system propagates reverse remodeling of cardiac muscle tissue by delivering a constant but minimal electrical direct current equivalent to physiological microcurrents. According to data published in the ESC Heart Failure journal, patients have maintained therapeutic benefit even after the device is turned off, distinguishing C-MIC from other device-based interventions.

Market Opportunity: Heart failure affects nearly 57 million people worldwide and represents one of the most significant unmet needs in cardiology. Most existing device-based therapies only manage symptoms rather than addressing the underlying cause and reversing disease progression.

Update: In September 2025, Berlin Heals announced the successful close of a new A2 funding round, adding to the momentum built from its prior A1 raise earlier in the year. The new funds will support the completion of the CMIC-III trial, a first-in-man study evaluating a less invasive, outpatient implantation approach, as well as preparations for future double-blind studies and further testing for an eventual FDA IDE study submission.

EndoQuest Robotics

Company Insights: EndoQuest Robotics is developing a fully flexible, endoluminal surgical robotics system designed to perform complex procedures through natural orifices, eliminating the need for incisions. The company’s Endoluminal Surgical (ELS) System aims to reduce recovery time, preserve healthy tissue, and unlock a new era of scar-free surgical care. With IDE approval in hand and multiple sites actively enrolling, EndoQuest’s pivotal PARADIGM trial is underway, marking a significant step toward transforming how complex colorectal lesions are treated.

Market Opportunity: Flexible endoluminal robotic systems represent a new frontier in minimally invasive surgery, addressing unmet needs in gastrointestinal procedures. According to LSI’s Global Surgical Procedure Volumes Database, in 2024, the global volume of applicable ENT, general, OB/GYN, and urologic procedures totaled approximately 90 million. 

Update: In July 2025, EndoQuest closed a Series D-2 funding round co-led by Crescent Enterprises and Dr. Fred Moll, a pioneer in medical robotics. Additional investors included Puma Venture Capital and UTHealth Houston. The round will support the pivotal PARADIGM trial, FDA regulatory efforts, upper GI feasibility studies, and continued development of advanced endoluminal visualization technologies.

Interventional Systems

Company Insights: Interventional Systems is rethinking surgical robotics with Micromate™, its CE-marked and FDA-cleared table-mounted robotic system for needle-based interventions. Unlike large and expensive general surgery robots, Micromate is portable, compact, and designed for high precision in percutaneous procedures. The platform is already in use through partnerships with Medtronic and Alphatec Spine, and the company offers a full suite of regulatory, manufacturing, and consulting services to strategic partners.

Market Opportunity: The surgical robotics market is one of the fastest-growing segments in medtech, projected to grow at a CAGR of 11.6% from $7.9 billion in 2023 to $13.7 billion in 2028. All subsegments within LSI’s analysis are experiencing double-digit growth, as hospitals and ambulatory centers seek more accessible and efficient robotic solutions.

Update: In September 2025, Interventional Systems entered a co-marketing agreement with Siemens Healthineers to jointly promote robotic-assisted procedures. The collaboration pairs Micromate with Siemens’ angiography suite technologies, aiming to enhance procedural precision, speed, and confidence for interventional radiologists worldwide.

Explore More in Compass

To dive deeper, purchase a subscription to LSI’s Compass, your resource for reliable data on thousands of private medtech companies, plus comprehensive market forecasts and insights to help you navigate opportunities with confidence.